← All candidates
Nine insider buys in the last year — $71.34M in all.
16 filings on record.
SCTXScribe Therapeutics, Inc.
NasdaqGM · Healthcare · $500.02M
$31.34
+7.61% · Sep 15
Nine insider buys in the last year — $71.34M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 6 buys
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$500.02M
Float
0.9M
6% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
13.8
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Aghazadeh Behzad
Bought $35.00M on Jul 24 — 2,333,333 sh @ $15.00, held indirect, 77% of their stake.
No completed positions to measure
Director
Gordon Carl L
Bought $15.00M on Jul 27 — 1,000,000 sh @ $15.00, held indirect, 74% of their stake.
No completed positions to measure
Director
Orbimed Advisors LLC
Bought $15.00M on Jul 27 — 1,000,000 sh @ $15.00, held indirect, 74% of their stake.
1 of 2 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
8 more transactions on Pro →Context
Wall St
$56.00 avg target
+78.7% vs today · 3 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 1 quarters beat
Q2 '26−$2.62 act+$1.10
The file stays open
16 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice